Basal Insulin Titration: Moving Towards a More Patient-Centric Approach with Gla-100 in India

Area of Science:

• Endocrinology
• Metabolic Diseases

Background:

• Type 2 diabetes mellitus (T2DM) is a progressive disease requiring insulin dose adjustments for glycemic control.
• Titration inertia, the failure to adjust insulin doses, is a significant barrier to effective T2DM management, particularly in Asian populations.
• Basal insulin, with its low hypoglycemia risk, offers a potential solution for optimizing insulin therapy.

Purpose of the Study:

• To explore the role of basal insulin, specifically insulin glargine 100 U/mL (Gla-100), in overcoming titration inertia in T2DM patients.
• To highlight the benefits of individualized, patient-centric titration algorithms for managing T2DM.
• To assess the feasibility of implementing patient-centric approaches in regions like India.

Main Methods:

• Review of existing guidelines and literature on basal insulin therapy and titration algorithms for T2DM.
• Focus on insulin glargine 100 U/mL (Gla-100) due to its safety profile (low hypoglycemia risk) and efficacy.
• Discussion of patient-centric approaches and their challenges in implementation.

Main Results:

• Insulin glargine 100 U/mL (Gla-100) demonstrates efficacy in glycemic control with a low risk of hypoglycemia, making it suitable for overcoming titration inertia.
• Simple, individualized titration algorithms using basal insulin can empower both physicians and patients.
• Patient-centric approaches, while challenging, are achievable and beneficial for optimizing T2DM management.

Conclusions:

• Insulin glargine 100 U/mL (Gla-100) is a valuable tool for addressing titration inertia in T2DM.
• Implementing patient-centric, basal insulin titration strategies can lead to improved glycemic control and patient outcomes.
• Overcoming titration inertia is crucial for optimizing insulin therapy in T2DM, especially in diverse healthcare settings.